Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Robert Kahn"'
Autor:
Laura Mitchell, Jennifer Oehler, Robert Kahn, Susan Sprigg, Grant Mussman, Melinda Corcoran, Chris Alexander
Publikováno v:
BMJ Open Quality, Vol 12, Iss Suppl 4 (2023)
Externí odkaz:
https://doaj.org/article/307c9f86b19d490195e5c379fc8a2a1e
Publikováno v:
BMJ Open Quality, Vol 12, Iss Suppl 4 (2023)
Externí odkaz:
https://doaj.org/article/ccedbaf882c94d11978b9524ea7cd44a
Autor:
Robert Kahn
Publikováno v:
Public Governance, Administration and Finances Law Review, Vol 6, Iss 2, Pp 7-20 (2022)
The “living together” concept poses a puzzle. Why did Europeans decide that life in a modern democracy requires showing one’s face? One explanation is opposition to Muslims and Islam. But the enforcement of face veil bans against non-religious
Externí odkaz:
https://doaj.org/article/65a94bbe3aa24bd192276f55b2c049e6
11 Getting it right, right now, while building services ready for future health needs of populations
Publikováno v:
BMJ Open Quality, Vol 10, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/78ba30115d6d41169a390ac011034c31
Autor:
Allison Parsons, Ndidi I. Unaka, Constance Stewart, Jennifer Foster, Valerie Perez, Nana‐Hawa Yayah Jones, Robert Kahn, Andrew F. Beck, Carley Riley
Publikováno v:
Learning Health Systems, Vol 5, Iss 3, Pp n/a-n/a (2021)
Abstract Introduction Despite learning health systems' focus on improvement in health outcomes, inequities in outcomes remain deep and persistent. To achieve and sustain health equity, it is critical that learning health systems (LHS) adapt and funct
Externí odkaz:
https://doaj.org/article/3f3327762bfe400c8e8fb2d07dccaa0a
Autor:
Melissa Klein, Andrew Beck, Robert Kahn, Adrienne Henize, Jennifer O'Toole, Alicia Alcamo, Daniel McLinden
Publikováno v:
MedEdPORTAL, Vol 9 (2013)
Abstract Introduction Social determinants of health (SDH) are emerging as a major barrier to the promotion of child health in the twenty-first century. The effects of poverty, including food insecurity, unsafe housing conditions, inadequate education
Externí odkaz:
https://doaj.org/article/c8427bfd382c4041ae93b74eaa1c15bf
Autor:
Howard A. Burris, Eric W. Humke, Daniel Maslyar, Anjali Vaze, Eva Schuth, Vanessa Lemahieu, Stephanie Royer-Joo, Katie Wood, Kedan Lin, Jian Xu, Divya Samineni, Randall C. Dere, Robert Kahn, YounJeong Choi, David S. Shames, Yulei Wang, Valerie Westcott, Julie Cordova, David R. Spigel, Joan H. Schiller, Maria Martinez Garcia, Enriqueta Felip, Miguel Martín, Sarah B. Goldberg, Michael S. Gordon, Jeffrey R. Infante, David E. Gerber
Supplementary Figure S1. CA125 response to lifastuzumab vedotin in ovarian cancer patients. All patients with radiographic responses also had {greater than or equal to}50 decrease in CA125 from baseline levels.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38becf22c0cb4090fc7526cc5dc5f7b1
https://doi.org/10.1158/1078-0432.22474400.v1
https://doi.org/10.1158/1078-0432.22474400.v1
Autor:
Howard A. Burris, Eric W. Humke, Daniel Maslyar, Anjali Vaze, Eva Schuth, Vanessa Lemahieu, Stephanie Royer-Joo, Katie Wood, Kedan Lin, Jian Xu, Divya Samineni, Randall C. Dere, Robert Kahn, YounJeong Choi, David S. Shames, Yulei Wang, Valerie Westcott, Julie Cordova, David R. Spigel, Joan H. Schiller, Maria Martinez Garcia, Enriqueta Felip, Miguel Martín, Sarah B. Goldberg, Michael S. Gordon, Jeffrey R. Infante, David E. Gerber
Purpose:This phase I trial assessed the safety, tolerability, and preliminary antitumor activity of lifastuzumab vedotin (LIFA), an antibody–drug conjugate of anti-NaPi2b mAb (MNIB2126A) and a potent antimitotic agent (monomethyl auristatin E).Pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dcfaf1467d4088929a6f4be22f3b838
https://doi.org/10.1158/1078-0432.c.6528776.v1
https://doi.org/10.1158/1078-0432.c.6528776.v1
Autor:
Bruce D. Cheson, Yu-Waye Chu, Surai Jones, Hsin-Ju Hsieh, Randall C. Dere, Priya Agarwal, Dan Lu, Robert Kahn, Sreeni Yalamanchili, Ephraim Hochberg, Julie E. Chang, Andre Goy, Mark Brunvand, Andy Chen, Daniel Lebovic, Ranjana H. Advani
Supplementary Figure 1. Summary of study enrollment by dose level and disease cohort. All patients were evaluated for safety and anti-tumor activity. Supplementary Table 1. Enrollment. Supplementary Table 2. Treatment-emergent adverse events occurrin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d31e3bf32a68a0e9dac40bce9607c21d
https://doi.org/10.1158/1078-0432.22467359.v1
https://doi.org/10.1158/1078-0432.22467359.v1
Autor:
Howard A. Burris, Eric W. Humke, Daniel Maslyar, Anjali Vaze, Eva Schuth, Vanessa Lemahieu, Stephanie Royer-Joo, Katie Wood, Kedan Lin, Jian Xu, Divya Samineni, Randall C. Dere, Robert Kahn, YounJeong Choi, David S. Shames, Yulei Wang, Valerie Westcott, Julie Cordova, David R. Spigel, Joan H. Schiller, Maria Martinez Garcia, Enriqueta Felip, Miguel Martín, Sarah B. Goldberg, Michael S. Gordon, Jeffrey R. Infante, David E. Gerber
Supplementary Figure S2. Representative NaPi2b ICH images for PROC and NSCLC patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f4792574451e294405cc4ee7c39e46f
https://doi.org/10.1158/1078-0432.22474397
https://doi.org/10.1158/1078-0432.22474397